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Abstract
Porcine reproductive and respiratory syndrome virus (PRRSV) is the major pathogen in the pig industry. Variability of the
antigens and persistence are the biggest challenges for successful control and elimination of the disease. GP5, the major
glycoprotein of PRRSV, is considered an important target of neutralizing antibodies, which however appear only late in
infection. This was attributed to the presence of a ‘‘decoy epitope’’ located near a hypervariable region of GP5. This region
also harbors the predicted signal peptide cleavage sites and (dependent on the virus strain) a variable number of potential
N-glycosylation sites. Molecular processing of GP5 has not been addressed experimentally so far: whether and where the
signal peptide is cleaved and (as a consequence) whether the ‘‘decoy epitope’’ is present in virus particles. We show that the
signal peptide of GP5 from the American type 2 reference strain VR-2332 is cleaved, both during in vitro translation in the
presence of microsomes and in transfected cells. This was found to be independent of neighboring glycosylation sites and
occurred in a variety of porcine cells for GP5 sequences derived from various type 2 strains. The exact signal peptide
cleavage site was elucidated by mass spectrometry of virus-derived and recombinant GP5. The results revealed that the
signal peptide of GP5 is cleaved at two sites. As a result, a mixture of GP5 proteins exists in virus particles, some of which still
contain the ‘‘decoy epitope’’ sequence. Heterogeneity was also observed for the use of glycosylation sites in the
hypervariable region. Lastly, GP5 mutants were engineered where one of the signal peptide cleavage sites was blocked.
Wildtype GP5 exhibited exactly the same SDS-PAGE mobility as the mutant that is cleavable at site 2 only. This indicates that
the overwhelming majority of all GP5 molecules does not contain the ‘‘decoy epitope’’.
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Porcine reproductive and respiratory syndrome virus (PRRSV)
is one of the most important swine pathogens, causing enormous
economic losses. PRRSV is an enveloped virus and belongs to the
family Arteriviridae in the order Nidovirales, together with equine
arteritis virus (EAV), murine lactate dehydrogenase-elevating virus
(LDV) and simian haemorrhagic fever virus (SHFV) [1].
Originally, distinct genotypes were identified in Europe (type 1,
prototype: Lelystad virus, [2]) and North America (type 2,
reference strain: VR-2332, [3]) in the early 1990s. Meanwhile,
these viruses have spread worldwide, involving also the emergence
of highly virulent, type 2-related PRRSV in Asia since 2006 [4].
The positive-sense RNA genome of PRRSV encompasses
approximately 15 kb and contains a set of nested open reading
frames (ORF). Of these, ORF2–7 encode structural proteins of the
virus. The glycoproteins (GP) 2, 3, and 4 (expressed from ORF2,
3, and 4, respectively) form a heterotrimeric complex in the
membrane of the mature virus and are important for cell tropism
[5,6] and virus entry/uncoating by interaction with the essential
receptor CD163 [7]. ORF5 and 6 code for GP5 and M,
respectively, and form a heterodimer, probably by disulfide bond
formation [8], which is the major component of the viral envelope.
ORF7 encodes the nucleocapsid (N) protein, which complexes the
viral genome in the mature virion. There are two more proteins,
encoded by alternative reading frames in ORF2 (ORF2b,
encoding the envelope (E) protein) and ORF5 (ORF5a). All
structural proteins (possibly with the exception of the recently
discovered ORF5a protein [9,10]) are essential for infectivity. The
GP2/3/4 complex and E are dispensable for particle formation,
while GP5/M and N are absolutely required for assembly and
budding [11]. The major glycoprotein complex GP5/M is also
involved in virus entry by binding to the virus receptors
heparansulfate and sialoadhesin (CD169), mediating virus attach-
ment and receptor-mediated endocytosis [12].
The virus has a restricted cell tropism in vitro. In animals, it
enters and replicates in porcine alveolar macrophages, viral
antigen has also been detected in resident macrophages of various
lymphoid tissues as well as in other cell types [13]. Clinical
symptoms, appearing early after infection, are mainly respiratory
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in growing pigs and promote the manifestation of the ‘‘Porcine
Respiratory Disease Complex’’ (multifactorial respiratory disease).
In pregnant sows, infection often leads to reproductive failure
(abortion, premature farrowing). In neonatal piglets, mortality
rates are high [14,15].
Viremia is sustained for up to four weeks after infection. Beyond
that phase, however, the virus is typically not cleared from the
body, but is persistently present at a continuous low level of
replication, predominantly in lymphoid tissues, and continues to
be shed. Only after 4–6 months will the virus be cleared
completely from the body [16,17].
It is generally assumed that the host’s immune system is
incapable of setting up a robust immune response against the virus,
leading to this persistence phenomenon [18]. While there is a
strong antibody response directed against N and GP5 few days
after infection, these antibodies do not neutralize the virus [19].
Neutralizing antibodies, however, appear only late, after more
than four weeks after infection [19]. Their appearance coincides
with clearing of virus from blood. GP5 is considered one major
target of neutralizing antibodies [20,21], albeit not in all reports
[22]. Neutralizing epitopes were also described and mapped in
other PRRSV proteins, notably M [23] and – at least for the
European genotype 1– GP4 [24]. The importance of neutralizing
antibodies is reflected by the findings that serum from convales-
cent pigs [25] and passive transfer of neutralizing antibodies [26]
both provide protection to homologous challenge and clear virus
from blood.
GP5 encompasses 200 amino acids (in the North American
genotype 2) and comprises an N-terminal signal peptide directing
protein synthesis to the rough endoplasmic reticulum (ER),
followed by an ectodomain of roughly 30 amino acids, containing
several N-glycosylation sites, two of which (N44 and N51) are
highly conserved between GP5 of virus strains. The region
between residues 63 and 135 is hydrophobic and assumed to span
the membrane three times. The C-terminal part (135–200) is most
probably located in the cytosol, ending up in the virus interior. See
Fig. 1A for a topology sketch of the protein.
GP5 is not only the most variable structural protein of PRRSV,
but even one of the most variable proteins of all viruses [27]. This
explains why the currently available vaccines protect against a
homologous, but not a heterologous infection. Of note, there is a
hypervariable region at the border between signal peptide and
ectodomain. Since this region is rich in serine and asparagine
codons (AGC and AAC, respectively), this often leads to the
addition or loss of N-glycosylation sites (consensus sequence: N-X-
S/T). Serial passaging of virus (PRRSV type 2 reference strain
VR-2332) between pigs resulted in numerous mutations in GP5,
including the changes N33S and D34N, removing and adding
potential glycosylation sites, respectively [28]. The mutation D34N
was also observed during the course of infection when the viral
sequences in individual pigs were followed after experimental
infection with PRRSV VR-2332 for 132 days [29].
Besides variability of the main antigen GP5, persistence of
PRRSV poses the biggest challenge for the successful control and
elimination of the disease. Several hypotheses about the mecha-
nistic basis for persistence have been put forward (for review, see
[30,31]). Here, the focus shall be on the molecular requirements
for one of these controversially discussed hypotheses, the ‘‘decoy
epitope’’ hypothesis by Lopez and Osorio [32].
In GP5 of type 2 PRRSV (reference strain: VR-2332), a
neutralizing epitope was determined by Pepscan analysis [33] and
phage display [34] to comprise amino acids 37–44 (in the
ectodomain). This epitope was termed ‘‘epitope B’’ since another
epitope further upstream (residues 27–31, ‘‘epitope A’’) was
identified as well [34]. Epitope A elicits an early and strong, but
non-neutralizing antibody response, while epitope B appears to be
less immunogenic and induces a neutralizing antibody response
only late (see Fig. 1B). Thus, the hypothesis was put forward by
Lopez and Osorio that epitope A might work as a ‘‘decoy epitope’’
[32]. Decoy epitopes are non-neutralizing, immunodominant
epitopes which, when present, decrease the induction or reactivity
of antibodies against a nearby neutralizing epitope – a mode of
action that was shown to occur e.g. in GP41 of human
immunodeficiency virus [35]. For PRRSV of the European
genotype (type 1), a ‘‘decoy epitope’’ could not be identified so
far, but a neutralizing epitope was described [36].
The ‘‘decoy epitope’’ hypothesis makes the following predic-
tions: Initially after infection of pigs the ‘‘decoy epitope’’ must be
present in fully processed GP5. However, this epitope is situated in
(or near) the signal peptide. Thus, the extent and exact position of
signal peptide cleavage critically determines whether the ‘‘decoy
epitope’’ is present in mature GP5. Since peptides covering the
Figure 1. Schematic representation of PRRSV GP5 and its possible processing. (A), Topology of unprocessed PRRSV GP5 with signal
peptide (purple,,30 amino acids), ectodomain (blue,,30 residues), a hydrophobic transmembrane stretch (,70 amino acids, black) and a cytosolic/
virus-internal endodomain (,70 residues, black). The position of the C-terminal HA tag used in this study is indicated (dark grey). Membrane in light
grey. (B), Signal peptide cleavage is predicted to occur at two sites: either at A26|V27 (site 1) or A31|S32 (site 2) as indicated. The neutralizing epitope
(green) is present in all predicted variants, but the ‘‘decoy epitope’’ (magenta) is not preserved in the mature protein by cleavage at site 2. However,
bioinformatic prediction tools rely on the amino acid sequence alone and do not take into account possible carbohydrate attachment to non-
conserved glycosylation sites (red) located in the hypervariable region (yellow) and to conserved glycosylation sites (brown). The situation for PRRSV
type 2 reference strain VR-2332 is depicted.
doi:10.1371/journal.pone.0065548.g001
Processing of GP5
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complete (unprocessed) protein sequence were used for identifica-
tion of epitopes, it is not known whether the identified sequences
are present in mature GP5.
Later during replication of PRRSV, the ‘‘decoy epitope’’ must
be eliminated such that a neutralizing antibody response against
epitope B can be raised that may help to clear PRRSV from the
body. Elimination of the ‘‘decoy epitope’’ might be achieved by
mutations in the hypervariable region that affect signal peptide
cleavage. To allow for signal peptide cleavage, the residues at
positions –3 and –1 with respect to the cleavage site have to be
small and uncharged, e.g. alanines [37], and point mutations in
this region might create or destroy a cleavage site. In addition,
acquisition or shifting of glycosylation sites could be crucial in this
respect: Since both the initial core glycosylation and signal peptide
cleavage occur co-translationally by the ER-resident oligosac-
charyl transferase and signal peptidase, respectively [37,38], these
simultaneous processes could influence each other: Glycosylation
might interfere with signal peptide cleavage since the presence of a
bulky glycan structure might prevent accessibility of signal
peptidase to a cleavage site that would be suitable in principle.
Also, different porcine cells might process GP5 differentially such
that the signal peptide (including the ‘‘decoy epitope’’) is removed
in cells that are infected late in the course of infection.
Although the ‘‘decoy epitope’’ hypothesis makes precise
predictions regarding the primary structure of GP5, none of the
molecular requirements have been analyzed by biochemical
means. We therefore assessed experimentally whether and where
the signal peptide of GP5 is cleaved and whether this is influenced
by the presence or absence of glycans near the cleavage site.
Results
Signal peptide cleavage is not governed by a consensus sequence
like, for instance, N-glycosylation, but can be predicted bioinfor-
matically using SignalP 4.0 (www.cbs.dtu.dk/services/SignalP/,
[39]). We applied this tool to predict whether the signal peptide is
cleaved from GP5 proteins of the different Arterivirus species.
Surprisingly, very different results regarding the probability of
cleavage and the location of the cleavage site were obtained
(Table 1). Whereas GP5 of EAV is predicted to contain a usual,
short signal peptide (18 amino acids), which is cleaved with high
confidence (D score of 0.91), the signal peptide of SHFV-GP5 is
longer (41 amino acids) and predicted not to be cleaved. A value of
0.34 was calculated for the D score, which is below the threshold
for cleavage of 0.45. An intermediate D score of 0.64 was obtained
for cleavage of GP5 from LDV, and the values are 0.85 and 0.76
for GP5 from the reference strains of PRRSV type 1 and 2,
respectively.
In addition, two different cleavage sites are possible for the
North American (type 2) PRRSV (reference strain VR-2332).
Apart from the most probable cleavage site (A31|S32, here
designated ‘‘site 2’’), cleavage could also occur further upstream,
between alanine 26 and valine 27 (‘‘site 1’’). While SignalP 4.0
provides the D score for the most probable cleavage position only,
alternative possible cleavage sites can be considered by the ‘‘Y
score’’, which is reported for every residue. This score is 0.72 for
site 2 and slightly lower (0.667) for site 1 (see Table S1).
Intriguingly, the mature GP5 would be devoid of the ‘‘decoy
epitope’’ if signal peptide cleavage occurred at site 2, but the
sequence would be present upon cleavage at site 1 or if the signal
peptide remained uncleaved.
We consider it unlikely that the homologous protein from
different viruses of the same family is cleaved in some species and
not cleaved in others since this would generate proteins with very
different membrane topologies, which are unlikely to have an
identical function. Hence, SignalP 4.0 (despite its confidence of
around 90% [39]) might yield inaccurate results in the case of
Arterivirus GP5. Also, this prediction tool does not take into
account the potential use of glycosylation sites located near the
potential cleavage site(s). Glycosylation of these residues might
interfere with signal peptide cleavage since the presence of a bulky
glycan structure could prevent access of signal peptidase to a
cleavage site that would be suitable in principle.
Analyzing Signal Peptide Cleavage of GP5 in vitro using
Porcine Microsomes
We aimed at deciphering experimentally whether the signal
peptide of GP5 is cleaved and whether this is influenced by glycans
near the signal peptide cleavage site. To this end, we first
employed in vitro transcription/translation/translocation, the clas-
sical method to analyze signal peptide cleavage in ER-directed
membrane proteins [40]. In this cell-free assay, the gene of interest
is transcribed into RNA and translated into (unmodified) protein.
Signal peptide processing and glycosylation can only occur upon
supplying microsomal membranes (biochemical preparations of
ER/Golgi). By comparing protein sizes generated in the absence
and presence of microsomal membranes, conclusions can be
drawn on protein processing.
The open reading frame (ORF) encoding GP5 (strain VR-2332)
was cloned into the plasmid pCMV-TNT, including a C-terminal
HA tag to enable detection of the protein by Western blot. Based
on this construct (GP5–HA wt), a set of mutants was generated in
which the potential glycosylation sites N30 and N33 near the
predicted signal peptide cleavage position were replaced by
serines, individually or in combination (resulting in the mutants
GP5–HA N30S, GP5–HA N33S and GP5–HA N30S, N33S).
Table 1. Signal peptide cleavage prediction for GP5 of all
Arteriviruses.
















Representative N-terminal sequences (1–50) of GP5 of each member of the
Arterivirus genus: EAV, equine arteritis virus (strain Bucyrus, GenBank accession
number [ABI64076.1], PRRSV: porcine reproductive and respiratory syndrome
virus (type 1/European, strain Lelystad [AAA46278.1] and type 2/North
American, strain VR 2332 [AAD12129.1]), LDV: murine lactate dehydrogenase-
elevating virus (NCBI reference sequence [NP_042577.1]), SHFV: simian
hemorrhagic fever virus (NCBI reference sequence [NP_203550.1]). The
predicted signal peptide (in small letters) and the ‘‘D value’’ for the most
probable cleavage site (vertical bar) according to bioinformatics prediction with
SignalP 4.0 are indicated. (D is a measure for cleavage likelihood, threshold:
0.45– note that the signal peptide of SHFV is predicted not to be cleaved.)
Potential N-glycosylation sites are highlighted in bold (proven experimentally
for LDV [57]). For PRRSV type 2, two signal peptide cleavage sites are possible
(indicated with vertical bar). The decoy epitope (VLAN, in italics) would be
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Note that such variation has been described for natural isolates
[41]. The other two potential glycosylation sites (N44 and N51)
were left unchanged. There are no significant differences in the
parameters of signal peptide cleavage prediction as analyzed with
SignalP 4.0 between GP5–HA wt and the mutants thereof (see
Table S1). Note that glycans are not considered by these
predictions.
These constructs were used for in vitro transcription/translation
followed by SDS-PAGE and Western blot. When the plasmid
encoding the wildtype (wt) sequence of GP5 with HA tag was
employed, a protein with the apparent molecular mass of 19 kDa
was produced (Fig. 2A, leftmost lane). This is smaller than
calculated from the amino acid sequence of GP5–HA with signal
peptide (23.5 kDa), but specific as evidenced by a control reaction
using empty vector (Fig. 2A, lane 2). Thus, due to this aberrant
SDS-PAGE mobility of GP5, conclusions regarding signal peptide
cleavage cannot be drawn by simply comparing the observed with
the predicted molecular weight.
To achieve processing of the protein, we prepared microsomes
from the pancreas of a pig, the natural host of PRRSV. Upon
in vitro transcription/translation of GP5–HA wt in the presence of
these microsomes, an additional 26-kDa band appeared (Fig. 2A,
third lane), indicating that GP5 was translocated into the lumen of
the ER, where it was glycosylated. Since protein translocation
in vitro is never perfectly efficient, a subfraction of GP5–HA was
still present in the unprocessed form as evidenced by the 19-kDa
band.
In addition, another (albeit weak) band at around 23 kDa can
be discerned. As one glycan typically accounts for approximately
2.5 kDa [42], this subfraction of GP5 most likely lacks one
carbohydrate chain.
When GP5–HA N30S was made in the presence of the porcine
microsomes (lane 4), the same major band at 26 kDa was seen.
Since the removal of the glycosylation site N30 did not reduce the
electrophoretic mobility of the protein, this site is either not used
or not present in the processed protein (due to cleavage of the
signal peptide).
In contrast, removal of the glycosylation site at position 33
(GP5–HA N33S, lane 5) reduced the molecular weight of the
expressed protein to around 23 kDa. Thus, N33 is used as a
glycosylation site in GP5. The mutant GP5–HA N30S, N33S (with
additional replacement of the N30 glycosylation site, lane 6), albeit
only poorly expressed or unstable under the experimental
conditions, ran like the N33S mutant in SDS-PAGE. – Overall,
the band pattern indicates that N33, but not N30, is used as a
glycosylation site in the vast majority of GP5 molecules.
To assess whether the signal peptide had been removed during
processing of GP5–HA in the presence of microsomes, the N-
linked glycosylations were removed from the proteins by treating
the samples with peptide-N-glycosidase F (PNGase F). Deglycosy-
lated GP5–HA should have the same size as GP5–HA synthesized
in the absence of microsomes if the signal peptide is not cleaved,
but would be smaller by 3 kDa if the signal peptide is absent in the
mature protein. When GP5–HA produced with microsomes was
digested with PNGase F, a major band at 16 kDa appeared
(Fig. 2B, lane 3), which runs well below GP5–HA produced
without microsomes (lane 1), indicating that the signal peptide was
cleaved. Yet, the 19-kDa band remained unchanged by this
treatment, yielding further evidence that it corresponds to
unprocessed protein. When the GP5–HA glycosylation mutants
were deglycosylated with PNGase F, the same band pattern as for
GP5–HA wt was seen (Fig. 2B; the weak bands above 19 kDa are
probably due to incomplete PNGase F digestion). Thus, removal
of neighboring glycosylation sites does not affect signal peptide
cleavage, neither qualitatively nor quantitatively. However, it is
difficult to precisely assess the efficiency of signal peptide cleavage
since translocation and glycosylation are not 100% efficient and
also vary between microsome preparations.
Analyzing Signal Peptide Cleavage of GP5 in Transfected
Cells
To overcome these technical limitations of in vitro transcription/
translation, the GP5–HA variants were expressed in cells, where
authentic processing of the protein can be expected. In addition to
the glycosylation mutants described above, another mutant (GP5–
HA D34N) was generated by introduction of a third potential
glycosylation site near the signal peptide cleavage site. This amino
acid exchange in GP5 was observed in the course of experimental
infection of pigs [29].
Figure 2. in vitro-transcription/translation of GP5–HA to assess processing (glycosylation/signal peptide cleavage). (A), Plasmids
encoding GP5–HA was subjected to in vitro-transcription/translation with rabbit reticulocyte lysate in the absence (–) or presence (+) of porcine
pancreatic microsomes. The products were analysed by SDS-PAGE and Western blot (anti-HA tag). Wildtype (wt) and mutants with deleted or added
glycosylation sites near the signal peptide cleavage site were employed; Ø, empty plasmid control. Molecular weight marker is indicated on the left-
hand side, arrows on the right-hand side show the positions of unprocessed GP5–HA (white), fully glycosylated GP5–HA (black), and GP5–HA lacking
one glycan (grey). (B), Glycans from the products of (A) were removed with PNGase F prior to SDS-PAGE and Western blot. Deglycosylated protein
lacking the signal peptide (black arrowhead) is smaller than unprocessed GP5–HA and deglycosylated protein containing the signal peptide (white
arrow), indicating signal peptide cleavage.
doi:10.1371/journal.pone.0065548.g002
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We transfected CHO-K1 cells, which are known for good
transfection efficiencies and expression rates, as well as MARC-
145 cells, which are permissive for PRRSV and therefore
particularly relevant for the assessment of GP5 processing [43].
SDS-PAGE and Western blot of cell lysates after transfection
showed that all GP5–HA variants were expressed and apparently
glycosylated (Fig. 3A, C). The comparison of electrophoretic
mobilities between mutants shows that GP5–HA N30S ran at the
same height as the corresponding wildtype. The size of the N33S
as well as the N30S, N33S mutant appears to be reduced by
roughly 2.5 kDa (one glycan). Limited digestion of GP5–HA wt
with PNGase F digestion showed that GP5 comprised three
glycans (Fig. 4). Thus, all the potential glycosylation sites except
N30 (i.e., N33, N44, and N51) were indeed used, which is in line
with previous investigations on PRRSV-GP5 [44]. The major
band of GP5–HA D34N is increased in size by one additional
glycan, showing that the additionally introduced glycosylation site
is used. The (weaker) band at the height of wildtype protein
indicates that this additional glycosylation is not realized in every
molecule, probably because the glycosylation sequons of N33
(N33N34S35) and N34 (N34S35S36) overlap.
Expression and glycosylation of the GP5–HA constructs was
comparable in CHO-K1 and MARC-145 cells. In the latter,
however, there was a prominent fraction of protein running at the
height of unprocessed protein as well (Fig. 3C). It is unclear
whether such a protein (which is likely to remain in the cytosol)
fulfills a specific function during the viral replication cycle or
whether it is an artifact of the expression system.
To assess the influence of glycosylation on signal peptide
cleavage, the lysates of the cells expressing variants of GP5–HA
was subjected to PNGase F digestion prior to SDS-PAGE and
Western blot. Representative results are shown in Fig. 3B (CHO-
K1 cells) and Fig. 3D (MARC-145 cells). A prominent band at
16 kDa was observed in the case of GP5–HA wt as well as all the
mutants under study. This protein clearly ran further in the gel
than unprocessed GP5–HA obtained from in vitro transcription/
translation in the absence of microsomes (thus not containing any
glycans and still having the signal peptide, cf. Fig. 2), which was
loaded on the gel as well as a control (rightmost lane in Fig. 3B/D).
Yet, there is also a relatively weak band at the height of
unprocessed protein, especially in the case of MARC-145 cells
(Fig. 3D), which most likely corresponds to unprocessed rather
Figure 3. Processing analysis of cell expressed GP5–HA to reveal glycan-independent signal peptide cleavage. CHO-K1 (A, B) and
MARC-145 (C, D; permissive for PRRSV) were transfected with plasmids encoding GP5–HA as wildtype (wt) and mutants with deleted or added
glycosylation sites near the signal peptide cleavage site; Ø, empty plasmid control. Cell lysates were subjected to SDS-PAGE and Western blot (anti-
HA tag) before (A, C) and after (B, D) deglycosylation with PNGase F. Molecular weight marker given on the left-hand side; arrows indicate sizes of
unprocessed GP5–HA (white), glycosylated protein (black: wildtype glycosylation; grey: lacking one glycan; black/+: with one additional glycan), and
deglycosylated protein without signal peptide (black arrowhead). In B and D, in vitro-generated GP5–HA (in the absence of microsomes, thus
intrinsically unprocessed, i.e. not glycosylated and still containing the signal peptide, cf. Fig. 2) is shown in the rightmost lane for size comparison.
Deglycosylated GP5–HA and all variants mostly ran faster than unprocessed protein.
doi:10.1371/journal.pone.0065548.g003
Figure 4. Limited PNGase F digestion of GP5–HA to show
modification with three glycans. MARC-145 cells were transfected
with the GP5–HA wt construct. Aliquots of the cell lysates were treated
with decreasing concentrations of PNGase F as indicated or left
undigested (Ø), then analyzed by SDS-PAGE and Western blot (anti-HA
tag). The number of carbohydrates cleaved by PNGase F decreases with
decreasing concentration. This causes a ladder-like appearance of
bands that allows counting of the total number of carbohydrates linked
to GP5–HA (arrowheads). The band denoted with the asterisk must not
be counted since it is also present in untreated GP5–HA and probably
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than deglycosylated protein since such a band was also present in
the lysate before PNGase F digestion (Fig. 3C).
To sum up, the signal peptide of GP5–HA appears to be
cleaved efficiently, independently of whether there are glycans in
the region of the signal peptide cleavage site. Furthermore, there
were no discernible differences in migration between the different
GP5–HA variants after deglycosylation with PNGase F, thus, the
presence or absence of glycans did not markedly shift the signal
peptide cleavage site.
Signal Peptide Cleavage of GP5 in Various Porcine Cells
The ‘‘decoy epitope’’ hypothesis predicts that at later time
points during natural infection of pigs, GP5 without ‘‘decoy
epitope’’ is produced that causes the generation of neutralizing
antibodies. Thus, it is possible that different porcine cells process
GP5 differentially resulting in a protein with uncleaved signal
peptide. To test signal peptide cleavage in porcine cells we first
isolated porcine alveolar macrophages (PAMs) from the lavage of
pig lung, but we were not able to detect expression of GP5–HA in
these PAMs using a variety of transfection procedures (data not
shown). Since primary cells are inherently difficult to transfect, we
analyzed processing of GP5 in various porcine cell lines, i.e.
monocytes and cells from intestine, kidney and testis. Cells were
transfected with the GP5–HA wt construct; lysates were subjected
to PNGase F digestion (Fig. 5B) or left untreated (Fig. 5A) and
probed by SDS-PAGE and Western blot. For comparison of
protein sizes, a sample from MARC-145 cells treated in the same
manner was included in the analysis (see Fig. 3). All the samples
from porcine cells had the same electrophoretic behavior as this
control sample. Thus, no differences in the use of glycosylation
sites were obvious, and the signal peptide was cleaved in all
porcine cells tested in the same way as in MARC-145 cells. Hence,
different porcine cell types do not differ with respect to processing
of GP5.
Signal Peptide Cleavage of GP5 from Various PRRSV
Strains
Next, it asked whether there are differences in signal peptide
cleavage between GP5 proteins from different PRRSV type 2
strains. We chose the representative virulent strain JXA-1 from the
outbreak in China [44] with a particularly high signal peptide
cleavage probability for GP5 (D score: 0.88, SignalP 4.0), as well as
GP5 from the US-American virulent strain Neb-1 [27,45], for
which a remarkably low signal peptide cleavage probability is
calculated (D score: 0.53, just above the threshold level). In
addition, GP5 from the attenuated modified live vaccine (MLV)
strain RespPRRS, which is derived from VR-2332 [46], was also
included in the analysis. While the various GP5 sequences all
contain the conserved glycosylation sites N44 and N51, they differ
with respect to the number of potential glycosylation sites in the
hypervariable region: GP5 of VR-2332 and RespPRRS contain
two potential glycosylation sites at positions 30 and 33 (of which
only N33 appears to be used in VR-2332, see Figures 2 and 3),
GP5 from JXA-1 has one additional site at position 34, and the
sequence from Neb-1 just comprises one glycosylation site in the
hypervariable region, located at position 30. Figure 6A depicts the
signal peptide/ectodomain sequences of the GP5 variants under
study, showing the number and position of potential glycosylation
sites and the most probable cleavage site according to SignalP 4.0.
However, only minor differences in the probability for cleavage at
site 1 and site 2 were predicted as presented in Table S1.
These different GP5 constructs, each with C-terminal HA tag,
were subjected to the same analysis as outlined above (transfection
of MARC-145 cells, lysis, PNGase F digestion, SDS-PAGE and
Western blot) to assess glycosylation and signal peptide cleavage
(Fig. 6). GP5–HA from MLV had the same size as from VR-2332,
indicating the same glycosylation pattern, i.e. no glycosylation at
the site N30. GP5–HA from JXA-1 produced also a (minor) band
with higher molecular weight, denoting that the overlapping
sequons at position 34 and 35 (NNSS) are both glycosylated in a
subfraction of molecules. Expression of GP5–HA from Neb-1
produced a band with a lower molecular weight, which implies
that only the two conserved glycosylation sites, but not the
glycosylation site at N30 are used. Note that GP5 variants of VR-
2332 and RespPRRS produced a very weak band with a similar
molecular weight. This indicates that one of the glycosylation sites
is not used in every molecule (see also Fig. 1 and 2 for a similar
band).
After deglycosylation of the different GP5–HA variants, all of
them showed the same electrophoretic mobility (Fig. 6C). Thus, no
difference in signal peptide processing could be discerned between
GP5 variants from different strains. Note that also GP5–HA
derived from Neb-1 was efficiently cleaved much though it is
predicted to have a just-above-the-threshold probability.
Analyzing Signal Peptide Cleavage of GP5 from Virus
Particles and from a Recombinant GP5–M Dimer by Mass
Spectrometry
The observed migration pattern of deglycosylated GP5–HA is
clear evidence for signal peptide cleavage; yet, the exact site of
signal peptide cleavage cannot be derived from these data. We
therefore employed mass spectrometry as a powerful tool to
unequivocally identify proteins and protein fragments. Immuno-
precipitation of cell-expressed GP5–HA does not yield enough
material for mass spectrometry (data not shown). Therefore, we
grew large quantities of PRRSV, strain VR-2332, in MARC-145
cells and partially purified the virus by PEG-8000 precipitation,
ultracentrifugation and sucrose density gradient centrifugation
Figure 5. The signal peptide of GP5–HA is cleaved in different
porcine cells. GP5–HA wt was expressed in MARC-145 cells as well as
different porcine cells, which were lyzed and analyzed by SDS-PAGE and
Western blot (anti-HA tag) before (A) and after (B) deglycosylation with
PNGase F. Labels as in Fig. 3. GP5–HA is processed in the same manner
in all cell types tested: PK-13 (porcine kidney), ST (testis), IEC Type I
(intestine), PSI (small intestine), and 3D4/21 (alveolar monocytic cell line
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(Fig. 7A). Virus proteins were subjected to PNGase F digestion to
remove glycans and were separated by SDS-PAGE and stained
with Coomassie. Deglycosylation is necessary to avoid heteroge-
neity in peptides due to the presence of differentially processed
carbohydrate side chains. In addition, as a result of deglycosylation
with PNGase F, asparagine is converted into aspartic acid and thus
the occurrence of D instead of N is evidence that a certain
glycosylation site is actually used. The band corresponding to GP5
(running at 16 kDa only after PNGase F digestion) was excised
from the gel (see Fig. 7A). The band was verified to be GP5 by
Western blot run in parallel, yielding a signal for GP5 at the same
height as the excised band (Fig. 7A, right-hand panel). Two
independent preparations were carried out.
In addition, GP5 (with a C-terminal His tag) was expressed in
Sf9 insect cells by use of the baculovirus expression system together
with the M protein, to which it is covalently linked by a disulfide
bond (data not shown). The protein dimer was enriched using Ni-
NTA, deglycosylated with PNGase F and separated by reducing
SDS-PAGE to excise the band corresponding to GP5, the identity
of which was confirmed by Western blot (anti-His tag, Fig. 7B).
The proteins were digested with either trypsin or chymotrypsin,
resulting peptides were eluted from the gel slices and subsequently
subjected to liquid chromatography-tandem mass spectrometry
(LC-MS/MS).
Processed GP5 was identified with high confidence in all
samples as the protein was the first hit in the MASCOT search,
where mass spectrometric fragments are matched with database
entries to determine protein identity. In the samples subjected to
trypsin digest, the fragment SDDSSSHLQLIYDLTL-
CELDGTDWLANK was detected. This corresponds to the
residues 32–59 of GP5 and thus the N-terminal fragment of
GP5 after signal peptide cleavage at site 2 (A31|S32). This peptide
contains three aspartic acid residues (D) instead of the asparagine
residues N33, N44 and N51, indicating that all three sites were
used. However, the mass of the peptide with unmodified
glycosylation site N33 (SNDSSSHLQLIYDLTLCELDGTDW-
LANK) was also present. This implies that not every GP5
molecule was glycosylated at N33. More importantly, no peptides
corresponding to signal peptide cleavage at site 1 (A26|V27) or
any other sites were recognized, nor were there any hints for GP5
fragments with the signal peptide retained at the N-terminus.
By chymotrypsin digest, more peptides were detected due to the
existence of more cleavage sites. The identified peptides that
correspond to parts of the GP5 ectodomain are listed in Table S2
and shown in Fig. 7C as black bars. Similarly to the trypsin
digestion, there were peptides originating from GP5 with signal
peptide cleavage at site 2 (A31|S32). Surprisingly though,
fragments derived from GP5 starting with V27 were also detected,
indicating that cleavage also occurred at site 1 (A26|V27).
Regarding glycosylation, up to three varieties of a peptide were
identified that differed in the modification of residues 30 and 33.
For example, the peptide 27–40 was detected as VLA-
DASDDSSSHLQ, VLANASDDSSSHLQ and VLA-
NASNDSSSHLQ, containing a D at position 30 and 33, a D
only at position 33 or no D. This indicates that N30 located
between cleavage sites 1 and 2 was glycosylated in a subfraction of
GP5 molecules, but only if N33 was also glycosylated.
Peptides starting with V27 as well as with S32, but not those
containing sequences from more N-terminal parts of the molecule,
were identified also in GP5 expressed with the baculovirus system.
This is evidence for use of signal peptide cleavage sites 1
(A26|V27) and 2 (A31|S32). Likewise, the sequence of those
peptides also indicates that either both N30 and N33, or only N33
or none of those sites were glycosylated.
Taken together, this experimental outcome implies that GP5’s
signal peptide is cleaved from every GP5 molecule. Surprisingly,
two cleavage sites, i. e. between A26 and V27 and between A31
and S32 were identified. These are the two sites that yielded values
above the threshold in signal peptide cleavage predictions with
SignalP 4.0. These two variants of GP5 are displayed in Fig. 7D.
Unfortunately, due to the number of peptides, quantitative
estimation is not feasible, but there was a tendency towards a
higher proportion of peptides derived from signal peptide cleavage
site 2. Thus, the sequence of the ‘‘decoy epitope’’ – situated
between site 1 and site 2– is present in a subset of mature GP5. A
subpopulation of GP5 molecules with the decoy epitope sequence
contains a carbohydrate at position 30, i.e. within the proposed
antibody binding region.
The Major Fraction of GP5 in Transfected Cells is Cleaved
at Signal Peptide Cleavage Site 2
Since the relative abundance of the two GP5 species could not
be determined by mass spectrometry, we endeavored to discrim-
inate biochemically between the two species. To this end, we
engineered artificial mutants of GP5–HA where signal peptide
Figure 6. The signal peptide of GP5 from different PRRSV type 2 strains is cleaved. (A), N-terminal sequences (residues 1–60) of
representative PRRSV type 2 strains (VR-2332: prototype strain, MLV: modified live vaccine ‘‘RespPRRS’’ (containing just one exchange – R13Q – in the
signal peptide/ectodomain region relative to VR-2332), JXA-1: Chinese virulent strain, Neb-1: US-American virulent strain) with potential glycosylation
sites (grey), predicted signal peptide (black), and propensity of signal peptide cleavage (D score according to SignalP 4.0, www.cbs.dtu.dk/services/
SignalP/). Note that the difference in signal peptide cleavage at site 1 and 2 was small as shown in detail in Table S1. (B/C), MARC-145 cells were
transfected with GP5–HA with the signal peptide/ectodomain sequence as depicted in (A), or with empty plasmid (Ø), subsequently lysed and
assessed by SDS-PAGE and Western blot (anti-HA tag) before (B) and after (C) PNGase F digestion to remove glycans. Labels as in Fig. 2; the thin black
arrow denotes additional glycosylation partially achieved in JXA-1; the number of glycans in the mature proteins is indicated on the bottom. The
black arrowhead in (C) indicates the position of deglycosylated GP5–HA without signal peptide.
doi:10.1371/journal.pone.0065548.g006
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cleavage is blocked by replacing relevant small, non-polar residues
near the cleavage sites by bulkier amino acids. SignalP 4.0 was
employed to evaluate and optimize these substitutions; the results
are given in Table S1. To generate a variant of GP5–HA with
uncleavable signal peptide (GP5–HA uncl.), the alanines at
positions 26, 29 and 31 were replaced by phenylalanine, tyrosine
and phenylalanine, respectively. To obtain GP5–HA cleaved at
exclusively site 1 (GP5–HA cl.1), site 2 was blocked by the
mutations A29S, A31Y. Likewise, cleavage at site 1 was blocked by
the mutations A26F, A29S (cleavage expected to be at site 2 only,
mutant GP5–HA cl.2).
Wildtype GP5–HA and these mutants were expressed in
MARC-145 cells and subjected to Western blot analysis before
and after PNGase F digestion of lysates (Fig. 8). For GP5–HA
uncl., a single band at the position of wildtype GP5–HA was
detected before digestion with PNGase F (Fig. 8A, third lane),
although a size increase by the retained signal peptide would be
expected. However, after removal of glycans by PNGase F
(Fig. 8B), this mutant exhibited a retarded SDS-PAGE mobility
relative to GP5–HA wt and ran at the position expected for
protein with uncleaved signal peptide (19 kDa). Limited PNGase F
digestion revealed that GP5–HA uncl. carries only two glycans
(Fig. 8C). It can be assumed that the glycosylation sites N30 and
N33, albeit present in the protein, were not modified, most
probably due to being held too close to the membrane by the
uncleaved signal peptide that might function as a signal-anchor
domain in that case.
GP5–HA cl.1 exhibited two bands after digestion with PNGase
F. The major band corresponds in size to GP5–HA uncl., implying
that the mutations unexpectedly prevented cleavage of the whole
signal peptide in a large fraction of molecules. The minor band of
deglycosylated GP5–HA cl.1 ran clearly lower than GP5–HA
uncl., but higher compared to GP5–HA wt and GP5–HA
cleavable at site 2 only, indicating that it was cleaved at site 1
(Fig. 8B). Two bands were also present for GP5–HA cl.1 before
digestion with PNGase F – a major band at the height of GP5–HA
wt/uncl./cl.2, and a weaker band increased in size by about 3 kDa
(Fig. 8A). The latter most likely corresponds to GP5–HA with
signal peptide cleavage at site 1 and carrying an additional glycan
at the site N30.
Figure 7. Identification of the signal peptide cleavage site of GP5 (virus-derived and recombinant) by mass spectrometry. (A), PRRSV
(strain VR-2332) was grown in MARC-145 cells, precipitated with PEG-8000, pelleted and subjected to sucrose density gradient centrifugation. The
virus-containing fraction was left untreated or deglycosylated with PNGase F and separated by reducing SDS-PAGE followed by Coomassie staining
(left-hand side) or Western blot (anti-GP5 antiserum, right-hand side). The deglycosylated band corresponding to GP5 (black box) was cut out of the
gel, digested with trypsin or chymotrypsin and analyzed by LC-MS/MS. (B), PRRSV GP5 (with His tag) and M (with HA tag) were co-expressed in Sf9
insect cells by infection with recombinant baculovirus. Following cell harvesting and lysis, GP5–M was enriched using Ni-NTA agarose (binding to
GP5–His). The eluated protein was left untreated or digested with PNGase F and subjected to reducing SDS-PAGE and Coomassie staining (left-hand
side) or Western blot (anti-His-tag antibody, right-hand side). The deglycosylated GP5 band (black box; coinciding with M) was cut out and treated as
in (A). (C), representative result from mass spectrometry of virus-derived GP5 (as in A). The first 61 residues of GP5 are shown with the positions of the
predicted chymotrypsin cleavage sites (black lines) and the putative signal peptide cleavage sites (broken lines). Chymotryptic peptides that were
identified are represented as black bars. The pattern of peptides is evidence for signal peptide cleavage at sites 1 and 2. No peptides corresponding
to the signal peptide region (1–26) were identified. (D), Conclusion from mass spectrometry, showing the N-terminal sequence of GP5 with signal
peptide (black), glycosylations (grey) and the positions of the neutralizing and the ‘‘decoy epitope’’. Two GP5 species exist with signal peptide
cleavage at sites 2 (top) and 1 (bottom), respectively.
doi:10.1371/journal.pone.0065548.g007
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Most inportantly, before and after digestion with PNGase F,
GP5–HA cl.2 ran exactly like wildtype, demonstrating that
cleavage of the latter also occurs at site 2.
In conclusion, the difference in the SDS-PAGE mobility
observed between GP5–HA cl.1 and cl.2 allows for discrimination
between GP5–HA cleavage at signal peptide cleavage sites 1 and
2. As wildtype GP5–HA behaved exactly like GP5–HA cl.2, but
unlike GP5–HA cl.1, it can be concluded that the vast majority of
GP5–HA wildtype is cleaved at signal peptide cleavage site 2.
Discussion
Despite the high medical and economic impact of PRRSV,
molecular details of its structural proteins are still sparse, but
relevant for virus pathogenicity. The major glycoprotein GP5 has
considerable immunological relevance since the ectodomain
harbors an epitope for neutralizing antibodies. However, the
generation of neutralizing antibodies is retarded in PRRSV
infection, which has been suggested to be one major cause for
the persistent phenotype of PRRSV infections that makes the
disease so difficult to control. GP5 from North American (type 2)
strains were hypothesized to possess a non-neutralizing, but
immunodominant ‘‘decoy epitope’’, located upstream from the
neutralizing epitope [32]. However, this ‘‘decoy epitope’’ is located
in (or near) the signal peptide and therefore its presence in mature
GP5 depends on whether (and where) the signal peptide is cleaved.
Moreover, the use of potential glycosylation sites in the
hypervariable region located between both epitopes could
influence signal peptide cleavage.
Here we show that the signal peptide is cleaved from GP5 of the
American PRRSV type 2 reference strain VR-2332, both upon
in vitro translation in the presence of microsomes (Fig. 2) as well as
in transfected cells (Fig. 3). Processing was not affected by deletion
and insertion of glycosylation sites in the vicinity of the cleavage
site, which also occurs in natural virus strains (Fig. 2+3). Likewise,
the signal peptide was also cleaved from different GP5 variants
derived from natural virus strains (attenuated and virulent ones).
These differ regarding the amino acids in the vicinity of the signal
peptide cleavage site and the number of glycans (Fig. 6). In
addition, a variety of porcine cell lines processed GP5 in the same
manner, as far as discernible by SDS-PAGE (Fig. 5). Mass
spectrometry of peptides derived from the GP5 of virus particles
and from a recombinant GP5/M dimer expressed in insect cells
unequivocally demonstrated that the signal peptide is cleaved from
every GP5 molecule (Fig. 7). Intriguingly, two different cleavage
sites were identified, which are identical to the sites predicted by
SignalP 4.0. Thus, there are probably two fractions of GP5
molecules present in virus particles, one with and one without the
‘‘decoy epitope’’. By comparing the wildtype GP5 probe to
mutants where either signal peptide cleavage site 1 or 2 was
blocked, we obtained circumstantial evidence that the largest part
of wildtype GP5 is cleaved at site 2 and will thus not contain the
‘‘decoy epitope’’ (Fig. 8). This is schematically displayed in Fig. 9.
Microheterogeneity was observed regarding the use of potential
glycosylation sites in the hypervariable region. GP5 without decoy
epitope was found to be present in virus preparations in two
variants: one containing and the other lacking carbohydrates at
position N33. The GP5 fraction containing the ‘‘decoy epitope’’
was even identified in three glycoforms: either without carbohy-
drates in the hypervariable region, glycosylated at N33 only or at
both N30 and N33.
Since mass spectrometry is an inherently non-quantitative
method, no definitive conclusions regarding the abundance of
each GP5 species are possible. However, the biochemical
experiments allow us to draw some conclusions about the use of
glycosylation sites in the hypervariable region. Since exchange of
N30 did not reduce the molecular weight of the GP5 probe
(Fig. 2+3), this glycosylation site is apparently used only in a very
small proportion of all GP5 molecules. In addition, limited
digestion of GP5–HA wt revealed that GP5 contains three
carbohydrates; a band with a higher molecular weight (implying
four glycans) was never observed, even after prolonged exposure of
the blots. In contrast, a weak GP5 band with only two
carbohydrates was seen in several blots (see Fig. 2, 3, 6) suggesting
that N33 is not glycosylated in every molecule. In summary, the
vast majority of GP5 molecules is glycosylated at N33 and at the
conserved glycosylation sites N44 and N51, confirming previous
data [44].
The analysis of glycosylation in the hypervariable region also
provides interesting insights into the cotranslational processing of
GP5. Generally, efficient N-glycosylation occurs only if the
glycosylation site is located at a certain distance (at least 12–14
amino acids) from the luminal membrane surface of the ER [47].
This condition is hardly fulfilled for the glycosylation sites N30 and
N33 when the nascent protein is membrane-anchored by the
Figure 8. The majority of GP5–HA molecules in transfected
cells is cleaved at site 2. MARC-145 cells were transfected with
variants of GP5–HA or with empty plasmid (Ø), subsequently lysed and
assessed by SDS-PAGE and Western blot (anti-HA tag) before (A) and
after (B) PNGase F digestion to remove glycans. wt: GP5–HA wildtype;
uncl.: Signal peptide (SP) cleavage completely blocked by mutation
A26F, A29Y, A31F; cl.1: SP cleavage possible at site 1 (A26|V27) only
(mutation A29S, A31Y); cl.2: SP cleavage at site 2 (A31|S32) only
(mutation A26F, A29S). Black arrow: GP5–HA with cleaved SP, carrying
three glycans, and/or GP5–HA comprising SP and two glycans; black
arrow with plus sign: GP5–HA, SP cleaved, four glycans; white arrow:
GP5–HA unprocessed/deglycosylated and containing the SP; grey and
black arrowhead: GP5–HA with SP cleavage at site 1 or 2, respectively.
(C), limited PNGase F digestion of GP5–HA uncl., performed and labeled
as in Fig. 4. The protein carries two glycans.
doi:10.1371/journal.pone.0065548.g008
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signal peptide (see Fig. 1A). Accordingly, the GP5 variant with
blocked signal peptide cleavage sites (GP5–HA uncl.) carried only
two glycans (Fig. 8C). In addition, there was a detectable quantity
of protein carrying four glycans upon analysis of the artificial
mutant GP5–HA cl.1, where signal peptide cleavage is only
possible at site 1 and N30 is thus preserved in the mature protein
(Fig. 8A).Thus, it is plausible that signal peptide cleavage precedes
glycosylation: First, signal peptide cleavage releases the protein
stretch containing N33 (and N30, if cleavage is at site 1) from the
membrane. This then allows the oligosaccharyl transferase to
attach core glycosylation to these residues. If signal peptide
cleavage and glycosylation of neighboring sites occur in such a
sequential manner, it is unlikely that glycan addition has an impact
on signal peptide cleavage. Indeed, deletion or addition of
glycosylation sites did not impede signal peptide cleavage in any
of our experiments.
While mass spectrometry could prove that there are mature
GP5 molecules that contain the ‘‘decoy epitope’’ sequence, the
combined biochemical data imply that the relative abundance of
this GP5 species is small or even minute. Assuming that the GP5
variants are incorporated into virus particles at the same ratio as
they are produced in transfected cells, mature virus particles
presumably comprise only very few ‘‘decoy epitope’’-containing
GP5 molecules. In light of these data, it is hard to grasp how
antibodies directed against such a small fraction of GP5 (cleaved at
site 1) should mask access of antibodies against the putative
neutralizing epitope. Besides, we cannot exclude that the fraction
of GP5 molecules containing a ‘‘decoy epitope’’ identified in our
virus preparations are actually a contamination, such as virus-like
particles (containing GP5/M dimers enwrapped in a lipid
membrane) that were not separated by gradient centrifugation
from infectious particles.
Overall, our results challenge, but do not ultimately falsify the
‘‘decoy epitope’’ hypothesis, since the small fraction of ‘‘decoy
epitope’’-containing GP5 could still be significant. Ultimate
clarification of this issue would require experimental infection of
pigs with recombinant viruses harboring a homogenous popula-
tion of GP5 molecules, either cleaved exclusively at site 1 (thus
completely maintaining the ‘‘decoy epitope’’) or exclusively at site
2 such that the ‘‘decoy epitope’’ is removed from all GP5
molecules. Planning of such mutations must also take into account
the presence of the overlapping open reading frame 5a, which
encodes the recently discovered membrane protein 5a [9,10]. This
was not considered when engineering the mutants GP5–HA cl.1
and cl.2. At least GP5–HA cl.2 was functionally processed in a
uniform manner (Fig. 8), demonstrating that this approach could
be feasible. Promising mutations should then be introduced into
the viral genome to test whether recombinant PRRSV can be
generated and whether it has growth properties similar to wildtype
virus. Finally, experimental infection of pigs with these PRRSV
variants could provide evidence whether the ‘‘decoy epitope’’ in
GP5 is required for the induction of persistent infection. Especially
recombinant viruses with GP5 completely lacking the ‘‘decoy
epitope’’ might induce neutralizing antibodies more quickly and
more robustly and could hence be promising candidates for a
vaccine. The immunogenicity of such variants might be further
improved by deletion of glycosylation sites in the hypervariable
region that do not affect signal peptide cleavage per se (Figs. 2–4)
and are not essential for virus replication, but induce higher levels
of neutralizing antibodies [44,48,49].
Material and Methods
Ethics Statement
Animal experiments were approved by the local state office of
occupational health and technical safety ‘‘Landesamt fu¨r Gesund-
heit und Soziales Berlin’’ (LaGeSo Reg. Nr. 0347/09).
Cells
Cell lines CHO-K1 (Chinese hamster ovary cells, ATCC CCL-
61), MARC-145 (simian kidney epithelial cells derived from MA-
104 [43], ATCC CRL-11171), PK-13 (porcine kidney epithelial
cells, ATCC CRL-6489), ST (swine testis cells, ATCC CRL-
1746), IEC Type I (swine intestinal epithelial cells, [50]), PSI
(porcine small intestinal cells, BioNutriTech, Lunel, France), and
3D4/21 (porcine alveolar monocytic cells, ATCC CRL-2843)
were maintained in adherent culture in Dulbecco’s Modified
Eagle’s Medium (DMEM, PAN, Aidenbach, Germany) supple-
mented with 10% fetal calf serum (Perbio, Bonn, Germany) at
37uC in an atmosphere with 5% CO2 and 95% humidity.
Suspension-adapted Sf9 and TriEx Sf9 cells were cultured in
Falcon Erlenmeyer flasks (BD Bioscience, Heidelberg, Germany)
in serum-free medium SF-900 II SFM (Invitrogen, Karlsruhe,
Germany) at 27uC with orbital shaking at 120 rpm.
Figure 9. Conclusion – Major fraction of GP5 from PRRSV type 2 does not contain the ‘‘decoy epitope’’. Schematic representation of
GP5 fractions as evidenced in this study. The signal peptide of GP5 is predominantly cleaved at site 2 (A26|V27; black arrow), but is also cleaved in
minor quantities at site 1 (A26|V27, thin grey arrow). The ‘‘decoy epitope’’ (magenta) is preserved only in GP5 cleaved at site 1. The neutralizing
epitope (green) is present in either case. Heterogeneity occurs also at non-conserved glycosylation sites (red). The fraction of GP5 with the ‘‘decoy
epitope’’ contains carbohydrates at either both N30 and N33, or only at N33 or none of these sites. A subfraction of site 2-cleaved GP5 does not
contain a carbohydrate at N33. Conserved glycosylation sites are in brown.
doi:10.1371/journal.pone.0065548.g009
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Plasmids
The nucleotide sequence encoding GP5 of PRRSV, strain VR-
2332, was in vitro-synthesized (Eurofins MWG Operon, Ebersberg,
Germany) including silent mutations to generate additional
restriction sites. Additionally, the sequence encoding a C-terminal
HA tag (amino acids YPYDVPDYA) was incorporated. The GP5-
ORF was subcloned into the plasmid pCMV-TNT (Promega,
Mannheim, Germany, containing T7 and CMV promoters) using
XhoI and NotI restriction sites to yield pCMV-TNT–GP5–HA wt.
Using this plasmid as a template, site-directed mutagenesis was
performed by overlap extension polymerase chain reaction (PCR)
using standard molecular biology techniques [51] to generate
GP5–HA mutants (VR-2332 GP5 with mutations N30S; N33S;
N30S, N33S; and D34N; other strains: mutagenesis in the signal
peptide/ectodomain region: R13Q [Neb-1]; E3G, G9C, S16F,
C24Y, F25L, A29V, D34N, S35N, L39I, N58Q [JXA-1] and
E3G, A29V, N33Y, D34S [Neb-1]). All plasmids were amplified in
E. coli XL-1 blue (Stratagene/Agilent, Waldbronn, Germany),
purified (PureYield Maxi Prep System, Promega, Mannheim,
Germany) and sequenced (GATC, Konstanz, Germany) before
use in experiments.
For recombinant protein expression of the GP5–M complex
using the baculovirus expression system, a bacmid was generated
that comprises the recombinant baculovirus genome. First, the
ORFs of GP5 and M were inserted into suitable MultiBac transfer
plasmids [52], which were obtained from ATG:Biosynthetics
(Merzhausen, Germany). The GP5 ORF was amplified from
pCMV-TNT–GP5–HA by PCR for cloning into the pACEBAC1
acceptor plasmid. The nucleotide sequence encoding a C-terminal
76histidine tag was incorporated into the reverse primer.
Likewise, the ORF encoding the M protein was amplified from
the pVR-V7 vector (full-length cDNA of PRRSV VR-2332, [53])
for cloning into the pIDC donor vector, including a C-terminal
HA tag. Both plasmids (pACEBAC1–GP5–His and pIDC–M–
HA) contain loxP sites to allow for plasmid fusion by Cre–lox
recombination, which was performed in vitro using Cre recombi-
nase (New England BioLabs, Frankfurt am Main, Germany)
according to the supplier’s protocol, followed by transformation of
E. coli DH5a and selection on Luria–Bertani broth agar plates with
gentamycin and chloramphenicol. Plasmid DNA was checked for
correctness by sequencing (GATC, Konstanz, Germany) and
inserted into baculovirus bacmid DNA by recombination using the
Bac-to-Bac system (Invitrogen, Karlsruhe, Germany).
In vitro Transcription/Translation
GP5–HA was generated by in vitro transcription/translation
using the TNT Quick Coupled Transcription/Translation System
(Promega, Mannheim, Germany). For the synthesis of unprocessed
protein, a reaction (25 mL) was typically composed of 20 mL rabbit
reticulocyte lysate (TNT master mix, also including T7 RNA
polymerase), 2.2 mL EasyTag Express [35S] protein labeling mix
(radioactively labeled methionine/cysteine, 20 mCi, Perkin-Elmer),
and 1 mg of pCMV-TNT–GP5–HA plasmid DNA. To synthesize
processed protein, canine pancreatic microsomal membranes
(Promega) or porcine pancreatic membranes (prepared as
described below) were included in the reaction (typically 1.6 mL).
Reactions were incubated for 90 min at 30uC. Subsequently, the
products were supplemented with glycoprotein denaturing buffer
(final concentrations: 0.5% SDS, 40 mM DTT) and incubated at
100uC for 10 min. For deglycosylation, aliquots of these denatured
samples were digested with 50–100 units peptide-N-glycosidase
(PNGase) F according to the manufacturer’s instructions (New
England BioLabs, Frankfurt am Main, Germany) for 4 h at 37uC.
Control samples were left untreated. The samples were supple-
mented with reducing SDS-PAGE loading buffer and assessed by
SDS-PAGE and Western blot (see below). The employment of
radioactively labeled amino acids allowed detection of in vitro-
synthesized protein by fluorography (as described, [54]), albeit
with numerous unspecific bands. Expression levels of individual
constructs varied largely from experiment to experiment (results
not shown).
Preparation of Porcine Pancreas Microsomes
Microsomal membranes were isolated from 20 g of pancreas
tissue from slaughtered pigs by a protocol adapted from Walter &
Blobel [55]. After mechanical removal of connective tissue, the
pancreas, kept in ice-cold buffer A (250 mM sucrose, 50 mM
triethanolamine, 50 mM potassium acetate, 6 mM magnesium
acetate, 1 mM EDTA, 1 mM DTT, 0.5 mM PMSF, pH 7.5, with
Complete protease inhibitor cocktail [Roche]; 4 mL/g tissue), was
homogenized with a fruit shredder followed by 42 strokes with a
Dounce homogenizer. Debris was pelleted by low-speed centrifu-
gation (6006g, 10 min, 4uC), the supernatant was then subjected
to a series of centrifugation steps to remove larger organelles (twice
at 10,000 rpm in a Beckman Ti-45 rotor for 20 min, and then
through a 1.3 M sucrose cushion in buffer A at 32,000 rpm in a
Ti-45 rotor for 150 min). The resulting white pellet was
resuspended in buffer B (250 mM sucrose, 50 mM triethanol-
amine, 1 mM DTT, pH 7.5 adjusted with acetic acid, 1.5 mL),
supplemented with EDTA (25 mM), incubated on ice for 30 min
and then pelleted through a 1.3 M sucrose cushion in a Beckman
Sw-55-Ti rotor at 40,000 rpm for 75 min, resuspended in buffer B
(1.5 mL), aliquotted, flash-frozen in liquid nitrogen and stored at
280uC.
Protein Processing Analysis in Cells
To assess processing of GP5–HA in cells, cells were seeded in
35-mm dishes and transfected with 4 mg of pCMV-TNT–GP5–HA
plasmid DNA using TurboFect (Fermentas/Thermo, St. Leon-
Rot, Germany). 24 h after transfection, cells were washed with
phosphate-buffered saline (PBS), detached from the dish with
trypsin–EDTA (PAN Biotech, Aidenbach, Germany), pelleted,
resuspended in 80 mL glycoprotein denaturing buffer (0.5% SDS,
40 mM DTT) and boiled for 10 min at 100uC. Typically, 15 mL
of this lysate was digested with PNGase F (2.5–5 units/mL, 4 h at
37uC) according to the manufacturer’s instructions (New England
BioLabs, Frankfurt am Main, Germany). For limited PNGase F
digestion, a serial twofold dilution of PNGase F (starting with 0.6
units/mL) was prepared for incubation with aliquots of the lysate in
the same manner. Control reactions were left untreated. After the
deglycosylation reaction, samples were supplemented with reduc-
ing SDS-PAGE loading buffer and subjected to SDS-PAGE and
Western blot.
SDS-PAGE and Western Blot
After sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE), typically using 15% polyacrylamide gels, gels were
either stained with Coomassie Brilliant Blue G-250 (Sigma-
Aldrich, Taufkirchen, Germany) or blotted onto polyvinylenedi-
fluoride (PVDF) membrane (GE Healthcare, Freiburg im
Breisgau, Germany) using standard methodology. After blocking
of membranes (blocking solution: 5% skim milk powder in PBS
with 0.1% Tween-20) for 1 h at 25uC, antibody was applied for
16 h at 4uC in blocking solution: rabbit-anti-HA tag antibody
(ab9110, Abcam, Cambridge, UK, 1:4,000) was used to detect
HA-tagged GP5, mouse-anti-His tag antibody (H1029, Sigma-
Aldrich, Taufkirchen, Germany, 1:3,000) was employed for
recombinant GP5–His, and virus-derived GP5 was detected with
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a polyclonal rabbit antiserum raised against peptide
LDTKGRLYRWRSPC, which corresponds to residues 146–158
of PRRSV VR-2332 GP5 with C-terminal cysteine (Genosphere
Biotechnologies, Paris, France, 1:1,000). After washing (3610 min
with PBST), suitable horseradish peroxidase-coupled secondary
antibody (anti-rabbit or anti-mouse, Sigma-Aldrich, Taufkirchen,
Germany, 1:5,000) was applied for 45 min at 25uC. After washing,
signals were detected by chemiluminescence using the ECLplus
reagent (Pierce/Thermo, Bonn, Germany) and a Fusion SL
camera system (Peqlab, Erlangen, Germany).
Preparation of PRRSV
MARC-145 cells in ten 15-cm dishes were infected with
PRRSV, strain VR-2332, at a multiplicity of infection (MOI) of
0.01 for 2 h and incubated for 4 days at 37uC, 5% CO2 in DMEM
+5% FCS. Upon occurrence of cytopathic effect, the supernatant
was harvested, cleared by low-speed centrifugation (3,0006 g,
5 min) and supplemented with polyethylene glycol (PEG)-8000
(Sigma-Aldrich, Taufkirchen, Germany) to a final concentration of
10% (w/v) at 4uC with gentle shaking for 18 h. The PEG-8000
precipitate was pelleted at 17,7006 g for 1 h at 4uC (Beckman
JLA-16,250), resuspended in HNE buffer (50 mM HEPES,
100 mM NaCl, 1 mM EDTA, pH 7,5) and applied on top of a
sucrose density gradient (20–60% (w/v) in TNE buffer: 10 mM
Tris?HCl, 10 mM NaCl, 1 mM EDTA, pH 7.5), which was
ultracentrifuged for 18 h at 35,000 rpm, 4uC, in a Beckman SW-
40 rotor. No distinct virus band was visible. The gradient was
divided into fractions, which were pelleted (Beckman SW-28,
27,000 rpm, 2 h, 4uC) and resuspended in TNE buffer. After
testing of the fractions for the presence of GP5 by Western blot,
the virus-containing fraction was denatured with glycoprotein
denaturing buffer (0.5% SDS, 40 mM DTT) for 10 min at 100uC
and then deglycosylated with PNGase F (New England BioLabs,
Frankfurt am Main, Germany) for 4 h at 37uC. Proteins were then
separated by SDS-PAGE. The band corresponding to GP5 was
excised with a scalpel and processed for mass spectrometry (see
below).
Production of Recombinant Baculovirus, Expression and
Enrichment of GP5–M
Sf9 insect cells (86105 cells) were seeded in a six-well plate in
Grace’s insect medium and allowed to attach (15 min at room
temperature), then transfected with 2 mg of bacmid DNA using
Cellfectin II (Invitrogen, Karlsruhe, Germany) according to the
supplier’s protocol. Four hours after transfection, medium was
replaced by Sf-900 II medium and cells were incubated for further
72 h at 27uC. Subsequently, supernatants were harvested, cleared
(centrifugation at 1,0006 g for 5 min), titrated (baculoQUANT
all-in-one kit, Oxford Expression technologies, Oxford, UK) and
stored at 4uC. Amplification of this ‘‘P1 virus stock’’ was
performed by infection of 50 mL TriEx Sf9 cells with this
supernatant at an MOI of 0.1 and incubation in suspension
culture (130 rpm) for 72 h, followed by collecting the supernatant
and titration. For protein expression, 16109 TriEx Sf9 cells at a
density of 26106 cells/mL were infected with high-titer virus
(MOI 2) and incubated in suspension culture. 72 h later, cells were
pelleted (4,0006g, 10 min), washed twice with PBS and stored at
280uC before lysis.
For enrichment of the GP5–M complex, cells were lysed in
80 mL of lysis buffer (50 mM NaPO4, pH 8.0, 500 mM NaCl, 1%
Triton X-100, 10 mM imidazole and Roche Complete protease
inhibitors) on ice for 45 min, then cleared from cellular debris by
centrifugation at 40,0006g for 45 min. Two milliliters of Ni-NTA
agarose (Qiagen, Hilden, Germany) was equilibrated by washing
twice with lysis buffer. Washed Ni-NTA agarose beads were added
to the clarified cell lysate and incubated for one hour with
occasional shaking at 4uC to allow binding of His-tagged GP5.
Beads were washed twice with lysis buffer, five times with 2 mL
wash buffer 1 (50 mM NaPO4, pH 8.0, 500 mM NaCl, 0.2%
Triton X-100, 20 mM imidazole), five times with 2 mL wash
buffer 2 (50 mM NaPO4, pH 8.0, 500 mM NaCl, 0.2% Triton X-
100, 40 mM imidazole). The protein was then eluted in five 1-mL
fractions using the elution buffer (50 mM NaPO4 pH 8.0,
500 mM NaCl, 0.2% Triton X-100, 250 mM imidazole). The
protein was then deglycosylated using PNGase F (New England
BioLabs, Frankfurt am Main, Germany) and separated by SDS-
PAGE, the band corresponding to GP5 was excised with a scalpel.
Protein Sample Preparation for Mass Spectrometry
After SDS-PAGE separation of proteins, excised protein bands
were washed with 50% (v/v) acetonitrile in 50 mM ammonium
bicarbonate/(NH4)HCO3, shrunk by dehydration in acetonitrile,
and dried in a vacuum centrifuge. Disulfide bonds were reduced
by incubation in 60 mL of 10 mM DTT in 50 mM (NH4)HCO3
for 45 min at 56uC. Alkylation was performed by replacing the
DTT solution with 55 mM iodoacetamide in 50 mM
(NH4)HCO3. The gel pieces were shrunk by dehydration in
acetonitrile, dried in a vacuum centrifuge, re-swollen in 20 mL of
50 mM (NH4)HCO3containing 100 ng trypsin (Promega, Madi-
son, WI, USA), and incubated at 37uC overnight. In the case of
chymotrypsin, excised protein bands were incubated with 110 ng
of enzyme (Roche Diagnostics, Penzberg, Germany) in 20 mL of
50 mM (NH4)HCO3 for 20 h at 25uC. Peptides were extracted
using 20 mL of 0.5% (v/v) trifluoroacetic acid (TFA) in acetonitrile
and the separated liquid was dried under vacuum. The samples
were reconstituted in 6 mL of 0.1% (v/v) TFA and 5% (v/v)
acetonitrile in water.
Liquid Chromatography-tandem Mass Spectrometry
LC-MS/MS analyses were performed on an Orbitrap Elite
hybrid mass spectrometer (Thermo Fisher, Bremen, Germany)
equipped with an UltiMate 3000 LC (Dionex). LC separations
were performed on a capillary column (Acclaim PepMap100, C18,
2 mm, 100 A˚, 150 mm675 mm i.d., Dionex) at an eluent flow rate
of 200 nL/min using a linear gradient of 3–30% eluent B in
33 min with further increase to 80% B at 40 min. Mobile phase A
contained 0.1% (v/v) formic acid in water, mobile phase B
contained 0.1% (v/v) formic acid in acetonitrile. MS data were
acquired in a data-dependent strategy selecting MS/MS fragmen-
tation events based on the precursor abundance in the MS scan.
LTQ MS/MS spectra were acquired with a target value of 20,000
ions. The maximum injection time for MS/MS was 300 ms, the
dynamic exclusion time was 30 s.
Data Processing
MS and MS/MS spectra were used to search against a custom-
made database containing all proteins of the SwissProt 2010_7
database (521,024 sequences; 183,901,752 residues) including the
full-length GP5 sequence. In addition, the database contains all
possible N-terminally truncated sequences of GP5 resulting from
signal peptide cleavage site prediction in the range between
residue 20 and 40. Asn/Asp amino acid exchanges were used as
variable modifications.For identification of GP5 peptides, the
processed MS/MS spectra were compared with the theoretical
fragment ions of GP5 peptides using the MASCOT server version
2.2.2 (Matrix Science Ltd., London, UK). The maximum of two
and six missed cleavages was allowed for tryptic and chymotryptic
Processing of GP5
PLOS ONE | www.plosone.org 12 June 2013 | Volume 8 | Issue 6 | e65548
peptides, respectively. The mass tolerance of precursor and
sequence ions was set to 10 ppm and 0.35 Da, respectively.
Supporting Information
Table S1 Amino acid sequences and signal peptide
cleavage site prediction for the GP5 sequences analyzed
in this study. For all GP5 variants under study, the sequence of
residues 20–40 is listed along with parameters from signal peptide
cleavage prediction using SignalP 4.0 (www.cbs.dtu.dk/services/
SignalP/): D score (likelihood of signal peptide cleavage
immediately before the site given in brackets), and Y scores for
‘‘site 1’’ (A26|V27) and ‘‘site 2’’ (A31|V32). The higher Y, the
more likely signal peptide cleavage at this site. Values above 0.5
can be considered ‘‘above the threshold’’. Most probable cleavage
site is indicated by Y score in bold. – In the sequence, the residues
in the predicted signal peptide are in small letters, the residues in
the mature protein in capital letters. Potential glycosylation sites
according to the sequon NXS/T are annotated in bold, the
‘‘decoy epitope’’ sequence (VLAN) is in italics in the GP5 sequence
from VR-2332 wt. – GenBank references: VR-2332
[AAD12129.1], MLV RespPRRS [AAD27656.1], JXA-1
[ABL60902.1], Neb-1 [ACE87854.1]. Full-length protein se-
quences were submitted to the SignalP 4.0 prediction.
(DOCX)
Table S2 Chymotryptic peptides identified by mass
spectrometry from virus-derived GP5 and from recom-
binantly expressed GP5. Representative list of ectodomain
peptides of deglycosylated GP5, digested with chymotrypsin, that
were identified by mass spectrometry (LC-MS/MS), source:
enriched PRRS virus particles and recombinant protein expres-
sion of GP5–M in Sf9 insect cells (Baculovirus system). Sequences
of peptides along with their observed and calculated masses,
number of missed chymotrypsin cleavage sites, and their ions score
(as a measure of confidence of the mass match and taken from the
MASCOT program). Note that glycosylated asparagine (N) is
converted to aspartic acid (D) by deglycosylation with PNGase F.
Peptides starting with V27 as well as with S32 were identified in
both types of sample, which is evidence for use of signal peptide
cleavage sites 1 (A26|V27) and 2 (A31|S32). – * The sequence
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